Penumbra to Present at Upcoming Investor Conferences

Penumbra to Present at Upcoming Investor Conferences

August 23, 2023 | Last Trade: US$293.17 2.79 -0.94

ALAMEDA, Calif., Aug. 23, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below:

Event:	2023 Wells Fargo Healthcare Conference
Date:	Wednesday, September 6, 2023
Time:	8:00am ET/5:00am PT
Event:	Baird 2023 Global Healthcare Conference
Date:	Tuesday, September 12, 2023
Time:	2:00pm ET/11:00am PT

Webcasts of the presentations will be available by visiting the investors' section of the company's website at www.penumbrainc.com. The webcasts will be available on the company's website for at least two weeks following the event.

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.

Investor Relations
Penumbra, Inc.
510-995-2461
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$293.17
Daily Change:	-2.79 -0.94
Daily Volume:	117,077
Market Cap:	US$11.480B

November 19, 2025 Penumbra to Present at the Piper Sandler 37th Annual Healthcare Conference November 05, 2025 Penumbra Reports Third Quarter 2025 Financial Results November 03, 2025 Penumbra: Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism October 27, 2025 Penumbra: Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism October 08, 2025 Penumbra Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025 LOAD MORE NEWS

Featured Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE